Exscientia

Exscientia/Recursion is one of the most ambitious AI drug discovery platforms available, combining massive proprietary datasets, an automated wet lab, and the BioHive-2 supercomputer built with NVIDIA. The key strength is the closed-loop system where experimental results continuously train AI models, enabling rapid target identification and molecule optimization. The company's pipeline includes several oncology and rare disease programs in Phase 1/2 trials, and they have demonstrated faster timelines from hit to IND compared to traditional methods. However, the platform is only accessible through direct enterprise partnerships — there is no self-service tier or transparent pricing. This makes it unsuitable for individual researchers or small biotechs without mature data infrastructure. The reliance on proprietary data also limits external validation. For large pharma partners, the platform's end-to-end capabilities and proven track record make it a strong choice. Smaller teams might prefer platforms like Insilico Medicine or Atomwise that offer more accessible, software-only solutions.

Exscientia, now part of Recursion, offers the Recursion Operating System (Recursion OS), an end-to-end AI drug discovery and development platform. It integrates over 50 petabytes of proprietary biological and chemical data spanning phenomics, transcriptomics, proteomics, ADME, and de-identified patient data. The platform uses machine learning models to identify drug targets and design optimized molecules, supported by an automated wet lab that runs millions of cell experiments per week. The results feed back into the system in a continuous loop. To process this data, Exscientia built BioHive-2 with NVIDIA, one of pharma's most powerful supercomputers. The platform is designed for large pharmaceutical companies and biotech firms, particularly in precision oncology, to reduce the high failure rate of traditional drug discovery. Exscientia's pipeline includes multiple oncology and rare disease programs, with several in Phase 1/2 clinical trials. The company powers its platform through strategic partnerships with industry leaders, technology partners like NVIDIA, and data partners.